Anciens postes connus de Richard Daifuku
| Sociétés | Poste | Fin |
|---|---|---|
Sonus Pharmaceuticals, Inc.
 Sonus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sonus Pharmaceuticals, Inc. engaged in the development of drugs for the treatment of cancer and related therapies. Its primary product TOCOSOL Paclitaxel, was an injectable paclitaxel emulsion for nonsmall cell lung cancer, ovarian cancer and bladder cancer. Sonus Pharmaceuticals was incorporated in 1991 and was headquartered in Bothell, WA. | Directeur Technique/Scientifique/R&D | 22/08/2008 |
Koronis Pharmaceuticals, Inc.
 Koronis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Koronis Pharmaceuticals, Inc. develops antiviral therapeutics based on viral decay acceleration. Its therapeutics are designed to inhibit a specific viral protein or enzyme, drugs based on VDA are designed to provoke the rapid decay of the targeted virus by further increasing its naturally high rate of mutation. The company was founded by Richard Daifuku in 1998 and is headquartered in Seattle, WA. | Fondateur | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Sonus Pharmaceuticals, Inc.
Sonus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sonus Pharmaceuticals, Inc. engaged in the development of drugs for the treatment of cancer and related therapies. Its primary product TOCOSOL Paclitaxel, was an injectable paclitaxel emulsion for nonsmall cell lung cancer, ovarian cancer and bladder cancer. Sonus Pharmaceuticals was incorporated in 1991 and was headquartered in Bothell, WA. | Health Technology |
Koronis Pharmaceuticals, Inc.
Koronis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Koronis Pharmaceuticals, Inc. develops antiviral therapeutics based on viral decay acceleration. Its therapeutics are designed to inhibit a specific viral protein or enzyme, drugs based on VDA are designed to provoke the rapid decay of the targeted virus by further increasing its naturally high rate of mutation. The company was founded by Richard Daifuku in 1998 and is headquartered in Seattle, WA. | Health Technology |